sorafenib has been researched along with Pregnancy in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 3 (50.00) | 2.80 |
Authors | Studies |
---|---|
Alonso, JC; Burgos, R; Casans, I; Espinoza, N; Fuster, D; González, FM; Oyagüez, I; Rodríguez, A; Sánchez, N; Williams, AO | 1 |
Aly, A; Benavente, F; Henriques, C; Kim, A; Malangone-Monaco, E; Noxon, V | 1 |
Azem, F; Fouks, Y; Goaz, S; Hasson, Y; Malcov, M; Sheiman, V | 1 |
Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E | 1 |
Alvares, C; Chakraborty, M; Conner, C; Gosrani, D; Mahdi, AJ; Rayment, R; Rees, A; Wilson, K | 1 |
Chen, H; Chen, HJ; Huang, Y; Li, X; Wei, Q; Wu, YJ; Xie, X; Yang, YR; Zeng, H; Zhou, Q; Zhu, YC | 1 |
1 review(s) available for sorafenib and Pregnancy
Article | Year |
---|---|
Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review.
Topics: Canada; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Microspheres; Pregnancy; Sorafenib | 2022 |
5 other study(ies) available for sorafenib and Pregnancy
Article | Year |
---|---|
Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Costs and Cost Analysis; Female; Health Care Costs; Humans; Liver Neoplasms; Male; Middle Aged; Pregnancy; Sorafenib; United States | 2020 |
Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours.
Topics: Abdominal Neoplasms; Adenomatous Polyposis Coli; Adult; Antineoplastic Agents; Female; Fertility Preservation; Fibromatosis, Aggressive; Humans; Oocyte Retrieval; Pregnancy; Preimplantation Diagnosis; Retrospective Studies; Sorafenib; Young Adult | 2021 |
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Dasatinib; DNA, Complementary; Female; Gene Dosage; Half-Life; Indoles; Male; Maternal-Fetal Exchange; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA; Sex Characteristics; Sorafenib; Sunitinib; Thiazoles | 2013 |
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pregnancy; Pregnancy Complications, Neoplastic; Sorafenib; Treatment Outcome | 2018 |
Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney Neoplasms; Neuroectodermal Tumors, Primitive; Niacinamide; Phenylurea Compounds; Pregnancy; Pyridines; Radiography; Sorafenib; Thrombosis; Vena Cava, Inferior | 2010 |